Healthcare provider profile · identity verified

Albert Sungwen Low, MD

Internal Medicine · BELLFLOWER, CA · NPI 1659448587

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	703	267
Amlodipine Besylate	Amlodipine Besylate	319	137
Losartan Potassium	Losartan Potassium	288	110
Lisinopril	Lisinopril	261	102
Metformin Hcl	Metformin Hcl	255	101
Rosuvastatin Calcium	Rosuvastatin Calcium	240	95
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	217	74
Levothyroxine Sodium	Levothyroxine Sodium	195	71
Potassium Chloride	Potassium Chloride	192	71
Atenolol	Atenolol	185	64
Glipizide	Glipizide	183	72
Omeprazole	Omeprazole	178	73
Simvastatin	Simvastatin	170	62
Gabapentin	Gabapentin	161	72
Terazosin Hcl	Terazosin Hcl	146	56
Hydrochlorothiazide	Hydrochlorothiazide	125	52
Meloxicam	Meloxicam	108	52
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	108	38
Furosemide	Furosemide	106	45
Tamsulosin Hcl	Tamsulosin Hcl	102	36
Pantoprazole Sodium	Pantoprazole Sodium	100	30
Allopurinol	Allopurinol	99	41
Metoprolol Tartrate	Metoprolol Tartrate	97	39
Spiriva Respimat	Tiotropium Bromide	97	23
Finasteride	Finasteride	94	33
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	85	30
Jardiance	Empagliflozin	82	32
Alendronate Sodium	Alendronate Sodium	81	32
Tramadol Hcl	Tramadol Hcl	80	30
Montelukast Sodium	Montelukast Sodium	79	32
Bisoprolol Fumarate	Bisoprolol Fumarate	77	31
Trazodone Hcl	Trazodone Hcl	74	34
Humulin N	Insulin Nph Human Isophane	71	22
Famotidine	Famotidine	67	35
Clopidogrel	Clopidogrel Bisulfate	63	26
Sertraline Hcl	Sertraline Hcl	62	24
Spironolactone	Spironolactone	61	25
Hydralazine Hcl	Hydralazine Hcl	56	30
Triamcinolone Acetonide	Triamcinolone Acetonide	55	33
Ibuprofen	Ibuprofen	53	24
Pradaxa	Dabigatran Etexilate Mesylate	52	17
Albuterol Sulfate Hfa	Albuterol Sulfate	49	30
Carvedilol	Carvedilol	47	16
Metformin Hcl Er	Metformin Hcl	46	21
Pravastatin Sodium	Pravastatin Sodium	45	16
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	44	19
Wixela Inhub	Fluticasone Propion/Salmeterol	43	21
Humulin R	Insulin Regular, Human	41	14
Duloxetine Hcl	Duloxetine Hcl	39	16
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	39	14
Humulin N Kwikpen	Insulin Nph Human Isophane	38	13
Pioglitazone Hcl	Pioglitazone Hcl	38	16
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	36	36
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	35	15
Fenofibrate	Fenofibrate	34	suppressed
Alvesco	Ciclesonide	32	20
Eliquis	Apixaban	32	16
Ozempic	Semaglutide	32	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	31	31
Fluticasone Propionate	Fluticasone Propionate	31	13
Mirtazapine	Mirtazapine	31	13
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	29	11
Azelastine Hcl	Azelastine Hcl	25	11
Digoxin	Digoxin	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	suppressed
Hydrocortisone	Hydrocortisone	20	12
Lactulose	Lactulose	20	14
Colchicine	Colchicine	19	12
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Midodrine Hcl	Midodrine Hcl	19	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Cephalexin	Cephalexin	17	17
Glipizide Er	Glipizide	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	16	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	14	14
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	13	suppressed
Prednisone	Prednisone	13	11
Donepezil Hcl	Donepezil Hcl	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Naproxen	Naproxen	11	suppressed
Tradjenta	Linagliptin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error